NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results